The preliminary core set for endpoints in disease controlling antirheumatic therapy includes
acute phase reactants. The objective of this clinically oriented literature review was to …

The preliminary core set for endpoints in ankylosing spondylitis (AS) clinical trials includes
physical function. The objective of this review was to compare properties and performance of …

Objectives Since the introduction of the German health care reform in January 2011, an early
benefit assessment (EBA) is required for all new medicines. Pharmaceutical manufacturers …

The aim of our study was to comprehensively review and critically appraise the cost domains
used in economic evaluations of the rheumatic diseases and to use this information to …

Objective To investigate 1) the magnitude of indirect costs, 2) changes in cost components,
and 3) correlations between changes in cost and social, clinical, and occupational variables …

Objective To report on the results of the consensus process integrating evidence from
preliminary studies to develop the first version of a Comprehensive ICF Core Set and a Brief ICF …

Objective: To report on the results of the consensus process integrating evidence from
preliminary studies to develop the first version of the Comprehensive ICF Core Set and the Brief …

Objective: To develop a systematic set of German cost data in rheumatoid arthritis (RA) based
solely on valid healthcare payer’s cost data sources. Methods: Retrospectively one year …

Objective To render information on the accuracy of patient‐reported indirect cost data
compared with payer‐derived data of the real indirect costs on a patient‐by‐patient basis …

Objectives We conducted a multi-stakeholder survey to determine key areas where a joint
European health technology assessment (HTA) could provide ‘additional benefit’ compared to …